Affiliation:
1. Consiglio Nazionale delle Ricerche Istituto di Scienze e Tecnologie Chimiche “Giulio Natta” (SCITEC) Milano 20131 Italy
2. Cardiovascular Theranostics Istituto Cardiocentro Ticino Ente Ospedaliero Cantonale Via Tesserete 48 Bellinzona CH‐6500 Switzerland
3. Institute for Research in Biomedicine Faculty of Biomedical Sciences Università della Svizzera italiana (USI) Bellinzona CH‐6500 Switzerland
4. Department of Molecular and Translational Medicine University of Brescia Viale Europa 11 Brescia 25123 Italy
5. Center for Colloid and Surface Science CSGI Florence 50019 Italy
6. Euler Institute Faculty of Biomedical Sciences Università della Svizzera Italiana Lugano 6900 Switzerland
Abstract
AbstractExtracellular vesicles (EVs), crucial mediators of cell‐to‐cell communication, hold significant diagnostic potential due to their ability to concentrate protein biomarkers in bodily fluids. However, challenges in isolating EVs from biological specimens hinder their widespread use. The preferred strategy involves direct analysis, integrating isolation and analysis solutions, with immunoaffinity methods currently dominating. Yet, the heterogeneous nature of EVs poses challenges, as proposed markers may not be as universally present as thought, raising concerns about biomarker screening reliability. This issue extends to EV‐mimics, where conventional methods may lack applicability. Addressing these challenges, the study reports on Membrane Sensing Peptides (MSP) as pan‐vesicular affinity ligands for both EVs and their non‐canonical analogs, streamlining capture and phenotyping through Single Molecule Array (SiMoA). MSP ligands enable direct analysis of circulating EVs, eliminating the need for prior isolation. Demonstrating clinical translation, MSP technology detects an EV‐associated epitope signature in serum and plasma, distinguishing myocardial infarction from stable angina. Additionally, MSP allow analysis of tetraspanin‐lacking Red Blood Cell‐derived EVs, overcoming limitations associated with antibody‐based methods. Overall, the work underlines the value of MSP as complementary tools to antibodies, advancing EV analysis for clinical diagnostics and beyond, and marking the first‐ever peptide‐based application in SiMoA technology.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献